Cynthia M. Ho
- Published in print:
- 2011
- Published Online:
- May 2011
- ISBN:
- 9780195390124
- eISBN:
- 9780199894536
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780195390124.003.0004
- Subject:
- Law, Intellectual Property, IT, and Media Law
This chapter provides a brief overview of TRIPS, with emphasis on provisions that impact patented and generic drugs. In particular, it discusses what TRIPS requires in terms of what must be patented, ...
More
This chapter provides a brief overview of TRIPS, with emphasis on provisions that impact patented and generic drugs. In particular, it discusses what TRIPS requires in terms of what must be patented, the scope of patent rights, and how patent rights are enforced for WTO member countries. In addition, it discusses the TRIPS requirement to protect some clinical data. This chapter answers some key questions, such as the following: Does TRIPS establish uniform patent standards? Do all WTO member countries need to provide patents on drugs? Does TRIPS prevent generic companies from relying on data of other companies in seeking regulatory approval? What happens if a WTO member country violates TRIPS?Less
This chapter provides a brief overview of TRIPS, with emphasis on provisions that impact patented and generic drugs. In particular, it discusses what TRIPS requires in terms of what must be patented, the scope of patent rights, and how patent rights are enforced for WTO member countries. In addition, it discusses the TRIPS requirement to protect some clinical data. This chapter answers some key questions, such as the following: Does TRIPS establish uniform patent standards? Do all WTO member countries need to provide patents on drugs? Does TRIPS prevent generic companies from relying on data of other companies in seeking regulatory approval? What happens if a WTO member country violates TRIPS?
Rajshree Chandra
- Published in print:
- 2010
- Published Online:
- October 2012
- ISBN:
- 9780198065579
- eISBN:
- 9780199080120
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780198065579.003.0006
- Subject:
- Law, Intellectual Property, IT, and Media Law
This chapter examines intellectual property rights in the context of the right to health. It presents the Novartis patent claim for the anti-cancer drug ‘Glivec’ in India as a case-study to highlight ...
More
This chapter examines intellectual property rights in the context of the right to health. It presents the Novartis patent claim for the anti-cancer drug ‘Glivec’ in India as a case-study to highlight the infringement of health rights in the context of the high prices of patented drugs, which make vital drugs inaccessible to a vast majority of people, particularly poor people. The case brings to the fore issues of drug patenting, survival of generic drugs, and their impact on access to medicines, which are vital to the preservation of the right to health, an aspect of human rights, as well as a constitutional rights in many countries.Less
This chapter examines intellectual property rights in the context of the right to health. It presents the Novartis patent claim for the anti-cancer drug ‘Glivec’ in India as a case-study to highlight the infringement of health rights in the context of the high prices of patented drugs, which make vital drugs inaccessible to a vast majority of people, particularly poor people. The case brings to the fore issues of drug patenting, survival of generic drugs, and their impact on access to medicines, which are vital to the preservation of the right to health, an aspect of human rights, as well as a constitutional rights in many countries.
P. J. Marshall (ed.)
- Published in print:
- 2005
- Published Online:
- January 2012
- ISBN:
- 9780197263518
- eISBN:
- 9780191734021
- Item type:
- book
- Publisher:
- British Academy
- DOI:
- 10.5871/bacad/9780197263518.001.0001
- Subject:
- History, Cultural History
This volume contains sixteen lectures given to the National Academy for the Humanities and Social Sciences in 2004. The topical issues debated in this volume include the patenting of AIDS drugs, the ...
More
This volume contains sixteen lectures given to the National Academy for the Humanities and Social Sciences in 2004. The topical issues debated in this volume include the patenting of AIDS drugs, the future pensions crisis (a lecture given by the Governor of the Bank of England), Britain's universities, and Pan-Islam. There are studies of Shakespeare, Pope, Montaigne, Robert Graves, and William Faulkner. And there are lectures on the Inquisition, empires in history, and the journey towards spiritual fulfillment.Less
This volume contains sixteen lectures given to the National Academy for the Humanities and Social Sciences in 2004. The topical issues debated in this volume include the patenting of AIDS drugs, the future pensions crisis (a lecture given by the Governor of the Bank of England), Britain's universities, and Pan-Islam. There are studies of Shakespeare, Pope, Montaigne, Robert Graves, and William Faulkner. And there are lectures on the Inquisition, empires in history, and the journey towards spiritual fulfillment.
- Published in print:
- 2010
- Published Online:
- March 2013
- ISBN:
- 9780226709178
- eISBN:
- 9780226709192
- Item type:
- chapter
- Publisher:
- University of Chicago Press
- DOI:
- 10.7208/chicago/9780226709192.003.0008
- Subject:
- History, History of Science, Technology, and Medicine
This chapter examines the growth of the biotechnology sector in Cuba. It explores Cuba's various attempts to define its biotechnology and its efforts to maintain a space for that science amid a ...
More
This chapter examines the growth of the biotechnology sector in Cuba. It explores Cuba's various attempts to define its biotechnology and its efforts to maintain a space for that science amid a rather differently couched global pharmaceutical norm. It mentions that the Center for Molecular Immunology's (CIM) TheraCIM drug was granted a U.S. patent in 1999 and an in-depth article on the CIM–York Medical partnership was featured in the July 2000 issue of Journal of the National Cancer Institute.Less
This chapter examines the growth of the biotechnology sector in Cuba. It explores Cuba's various attempts to define its biotechnology and its efforts to maintain a space for that science amid a rather differently couched global pharmaceutical norm. It mentions that the Center for Molecular Immunology's (CIM) TheraCIM drug was granted a U.S. patent in 1999 and an in-depth article on the CIM–York Medical partnership was featured in the July 2000 issue of Journal of the National Cancer Institute.
